Harmony Biosciences Holdings (HRMY) — Cash Flow Quality Index
Harmony Biosciences Holdings (HRMY) has a Cash Flow Quality Index of 0.85x as of March 2026. Operating cash flow of $27.76 Million is below net income of $32.49 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Harmony Biosciences Holdings (HRMY) cash conversion ratio to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Harmony Biosciences Holdings Cash Flow Quality Index (2021–2025)
Historical Cash Flow Quality Index for Harmony Biosciences Holdings across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Harmony Biosciences Holdings total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Harmony Biosciences Holdings (2021–2025)
Year-by-year earnings quality comparison for Harmony Biosciences Holdings. For live market cap and the full company financial profile, see Harmony Biosciences Holdings (HRMY) total market value.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.19x | $348.20 Million | $158.69 Million | ▲ +45.2% |
| 2024 | 1.51x | $219.82 Million | $145.49 Million | ▼ -11.3% |
| 2023 | 1.70x | $219.39 Million | $128.85 Million | ▲ +113.9% |
| 2022 | 0.80x | $144.47 Million | $181.47 Million | ▼ -72.1% |
| 2021 | 2.85x | $98.56 Million | $34.60 Million | — |